After falling as low at 5c per share in 2013, and spending more than two years trading below 50c, renewed interest in Impedimed has recently driven the share price as high as $1.82. So what's caused this astounding rally? Stuart Roberts, Life Sciences Analyst at NDF Research, explains that the change came in 2014 when the company gained the appropriate codes to allow them to be paid by the US healthcare system. "That has unlocked a big market opportunity. About 250,000 women get breast cancer every year, and about 30% of those patients are in danger of getting this condition called lymphedema, so there's a large market opportunity". As well as this, the product has significant potential in the massive cardiac market, and also as a personal health monitoring tool for the private market. In the video below, he discusses Impedimed's current market and these two new blue sky opportunities.